Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, and markets rapid diagnostic tests that detect infectious diseases. The company offers rapid tests for the detection of HIV antibodies, syphilis, and canine leishmaniasis. Its products include Lateral Flow Rapid HIV Tests and DPP HIV Test, which are qualitative Yes/No tests for the detection of antibodies to HIV 1 and 2 with visually interpreted results available within approximately 15 minutes. The company sells its products under its STAT PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners. Chembio Diagnostics sells its products to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has agreements with the Oswaldo Cruz Foundation relating to products based on its DPP technology; Bio-Rad Laboratories N.A. for the development of a six-band multiplex product on its DPP; and Infectious Disease Research Institute for the development and initial supply of a rapid point-of-care test for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.